Stay updated with breaking news from Restricted Use. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Central government is examining the recommendation of the Subject Expert Committee (SEC) regarding the grant of market authorization of Covaxin for the age group of 2 to 18 years for restricted use in an emergency situation subject to various conditions, Ministry of Health and Family Welfare (MoHF) told Rajya Sabha on Tuesday.
The Interim Phase II, III clinical trial data of COVAXIN on Healthy Volunteers aged 2 to 18 years submitted by Bharat Biotech was deliberated in the meeting of the Subject Expert Committee (SEC) on August 28 and October 11, informed Ministry of Health and Family Welfare.
The Central government is examining the recommendation to grant market authorization to Covaxin for the age group of 2 to 18 years.
The government said it is examining Pfizer's request for indemnity and will take a decision in the larger interest of people and on merit.
Pfizer told Indian authorities that its vaccine has demonstrated